Latest stories on DSGN
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
Seeking Alpha56 · neutralproduct/pr
Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program
Seeking Alpha63 · neutralanalyst
Design Therapeutics initiated with an Overweight at Wells Fargo
The Fly63 · neutralanalyst
Design Therapeutics management to meet with Oppenheimer
The Fly55 · neutralgeneral
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
Business Insider56 · neutralgeneral
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
StockTitan55 · neutralgeneral
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch
Yahoo Finance56 · neutralanalyst
Design Therapeutics GAAP EPS of -$0.32 beats by $0.02
Seeking Alpha56 · neutralearnings
Design Therapeutics, Inc. (DSGN) files 8-K
SEC 8-K50 · neutralgeneral
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Business Insider59 · neutralproduct/pr
A Deeper Dive Into Design Therapeutics
Seeking Alpha58 · neutralproduct/pr
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
Seeking Alpha67 · bullishproduct/pr
Design Therapeutics Stockholders Approve Director and Auditor at Meeting
TipRanks50 · neutralgeneral
Design Therapeutics, Inc. (DSGN) files 8-K
SEC 8-K50 · neutralgeneral
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference | DSGN Stock News
StockTitan56 · neutralgeneral
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia - Slideshow
Seeking Alpha50 · neutralgeneral
This Biotech Leader Ran Up As Much As 18% — And Then Lost It All
Yahoo Top42 · neutralgeneral
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Seeking Alpha56 · neutralproduct/pr
Design Therapeutics' DT-216P2 Yields Meaningful Biomarker and Clinical Gains in Friedreich Ataxia Trial
MarketChameleon73 · bullishproduct/pr
Jim Cramer on Design Therapeutics: “Pure Spec, Pure Spec”
Yahoo Finance42 · neutralanalyst